[CAS NO. 50-44-2]  6-Mercaptopurine

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [50-44-2]

Catalog
HY-13677
Brand
MCE
CAS
50-44-2

DESCRIPTION [50-44-2]

Overview

MDLMFCD00233552
Molecular Weight152.18
Molecular FormulaC5H4N4S
SMILESS=C1NC=NC2=C1NC=N2

For research use only. We do not sell to patients.


Summary

6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.


IC50 & Target

endogenous purines [1]


In Vitro

6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT00003671 Children´s Oncology Group|National Cancer Institute (NCI)
Leukemia
December 1998 Phase 2
NCT00187005 St. Jude Children´s Research Hospital
Acute Lymphoblastic Leukemia
July 1998 Phase 3
NCT02419469 M.D. Anderson Cancer Center|Jazz Pharmaceuticals
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
November 13, 2015 Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : 35.71 mg/mL ( 234.66 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.5712 mL 32.8558 mL 65.7117 mL
5 mM 1.3142 mL 6.5712 mL 13.1423 mL
10 mM 0.6571 mL 3.2856 mL 6.5712 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 50% PEG300 >> 50% saline

    Solubility: 3.33 mg/mL (21.88 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

6H-Purine-6-thione, 1,9-dihydro-
Purine-6-thiol
6H-Purine-6-thione, 1,7-dihydro-
Purine-6(1H)-thione
1,9-Dihydro-6H-purine-6-thione
6-MP
NSC 755
Leukerin
6-Mercaptopurine
7-Mercapto-1,3,4,6-tetrazaindene
Purinethol
Hypoxanthine, thio-
Mercaptopurine
Purinethiol
6-Mercaptopurin
3H-Purine-6-thiol
1H-Purine, 6-mercapto-
Mercaleukin
6-Thiopurine
6-Thioxopurine
Ismipur
Leupurin
Mercapurin
Mern
6-Thiohypoxanthine
9H-Purine-6(1H)-thione
Purine-6-thione
1,7-Dihydro-6H-purine-6-thione
Purimethol
Thiohypoxanthine
Mercaleukim
U 4748
NSC 55477
NSC 68293
Purixan
1,9-Dihydro-purine-6-thione
3,7-Dihydropurine-6-thione